Belharra Therapeutics

About Belharra Therapeutics

Belharra Therapeutics aims to redefine the concept of 'undruggable' proteins by illuminating novel binding pockets across the entire proteome to develop new therapeutics. Their mission is to make every protein druggable and ensure no disease remains untreatable.

Products & Services

Searchlight™ Platform:A chemoproteomics platform that identifies binding pockets on high-value, elusive drug targets across the undrugged proteome, in any protein or cell type.

Specialties

Chemoproteomics Drug Discovery Proteome Analysis Therapeutics Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 130000000 MR: - FA: $130 million FAN: 130000000	D: 2023-01-04 FD: 2023-01-04	2 investors

Series A Latest

2023-01-04

$130.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jeff Jonker

Chief Executive Officer

G

Gary O'Neill

Chief Scientific Officer

C

Chris Parker

Co-founder and Researcher

R

Richard Glynne

Interim Chief Executive Officer

S

Sean Buchanan

Chief Scientific Officer

J

Justin Ernst

Senior Vice President, Head of Chemistry

View 7 more team members with Pro

Unlock Full Team Directory

Recent News